... WhatsApp

New Treatment Improves Survival in Advanced Liver Cancer

You are here >> Home > Latest Updates > Colon Cancer Updates > New Treatment…

New Treatment Improves Survival in Advanced Liver Cancer 1

Liver cancer is one of the most common and serious cancers worldwide. Many patients are diagnosed when the cancer is already advanced, making treatment difficult. A new international study tested a combination of toripalimab (a type of immunotherapy) and bevacizumab (a drug that blocks blood supply to tumors) against sorafenib, the standard treatment for advanced liver cancer.

The trial included 326 patients from China, Taiwan, and Singapore who had not received any prior treatment. Patients were randomly given either the new drug combination or sorafenib.

The results showed that the combination of toripalimab and bevacizumab worked better than sorafenib. Patients lived longer without their cancer getting worse, and they also lived longer overall. On average, those who received the combination survived about 20 months, compared to 14.5 months for those who received sorafenib. This is a meaningful improvement for people facing advanced liver cancer.

Side effects were common in both groups, with some patients experiencing high blood pressure, bleeding in the stomach, or low blood counts. Most side effects could be managed, and the number of serious side effects was similar between the two groups.

This study suggests that toripalimab plus bevacizumab is a stronger first-line treatment option for advanced liver cancer compared to sorafenib. The combination is now approved in China and may offer new hope for patients and families facing this disease.

Rate this post
Robotic Cancer Surgery

Exclusive Health Tips and Updates

Best robotic cancer surgery in Ahmedabad
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.